$10.28
+0.16
(+1.58%)▲
In the last 1 year, Seagen Inc has given 43.0% return, outperforming this stock by 48.3%
2.24%
Downside
Day's Volatility :4.06%
Upside
1.86%
24.32%
Downside
52 Weeks Volatility :51.04%
Upside
35.31%
Period | Cullinan Oncology Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -10.36% | -0.3% | -6.7% |
6 Months | -18.58% | -8.8% | -6.2% |
1 Year | -5.33% | -4.2% | -5.1% |
3 Years | -66.17% | 23.0% | 26.9% |
Market Capitalization | 398.3M |
Book Value | $12.34 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 1.34 |
PE Ratio | 7.55 |
Wall Street Target Price | 28.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -21.03% |
Return On Equity TTM | 14.13% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 18.9M |
EBITDA | -160.1M |
Diluted Eps TTM | 1.34 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.67 |
EPS Estimate Next Year | -4.47 |
EPS Estimate Current Quarter | -0.98 |
EPS Estimate Next Quarter | -0.72 |
What analysts predicted
Upside of 177.24%
Sell
Neutral
Buy
Cullinan Oncology Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cullinan Oncology Inc | -1.65% | -18.58% | -5.33% | -66.17% | 33633.33% |
![]() Moderna, Inc. | -3.38% | -26.73% | -11.31% | 107.29% | 592.96% |
![]() Regeneron Pharmaceuticals, Inc. | -9.68% | -3.07% | 9.61% | 21.54% | 142.61% |
![]() Seagen, Inc. | -2.59% | 59.82% | 42.99% | 22.0% | 220.73% |
![]() Vertex Pharmaceuticals Incorporated | -5.71% | 2.81% | 21.09% | 13.49% | 111.23% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cullinan Oncology Inc | 7.55 | 7.55 | NA | -4.67 | 0.14 | -0.21 | 0.0 | 12.34 |
![]() Moderna, Inc. | 11.22 | 11.22 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.53 | 26.53 | 0.41 | 13.64 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cullinan Oncology Inc | Buy | $398.3M | 33633.33% | 7.55 | 0.0% |
![]() Moderna, Inc. | Buy | $48.1B | 592.96% | 11.22 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 142.61% | 19.72 | 33.81% |
![]() Seagen, Inc. | Hold | $36.3B | 220.73% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.0B | 111.23% | 26.53 | 35.4% |
MPM Oncology Impact Management LP
CHI Advisors LLC
Bvf Inc
Vanguard Group Inc
BlackRock Inc
American International Group Inc
Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.
Organization | Cullinan Oncology Inc |
Employees | 62 |
CEO | Mr. Nadim Ahmed |
Industry | Other Consumer Services |
Pennant Park Investment Corp
$5.52
-0.18%
iShares Trust - iShares Investment Grade Corporate Bond BuyWrite Strategy ETF
$33.71
+0.26%
LEMONADE INC
$17.62
+0.51%
INNOVATOR S&P 500 POWER BUFF
$29.83
-0.37%
Remark Holdings, Inc.
$1.21
-9.02%
FIDELITY D&D BANCORP INC
$37.80
-2.11%
IQ MacKay Municipal Intermediate ETF
$24.26
+0.25%
FT CBOE VEST US EQUITY DEEP
$34.72
-0.46%
FIRST TRUST EUROPE
$33.28
-1.26%